The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.

Mashal Ahmed, Isabelle Boileau, Bernard Le Foll, Andre F Carvalho, Stefan Kloiber

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 2022 Jan-Feb

filter terms:

Social anxiety disorder (SAD) is a highly prevalent psychiatric disorder that presents with an early age of onset, chronic disease course, and increased risk of psychiatric comorbidity. Current treatment options for SAD are associated with low response rates, suboptimal efficacy, and possible risk of adverse effects. Investigation of new neurobiological mechanisms may aid in the identification of more specific therapeutic targets for the treatment of this disorder. Emerging evidence suggests that the endogenous cannabinoid system, also referred to as the endocannabinoid system (ECS), could play a potential role in the pathophysiology of SAD. This review discusses the known pathophysiological mechanisms of SAD, the potential role of the ECS in this disorder, current drugs targeting the ECS, and the potential of these novel compounds to enhance the therapeutic armamentarium for SAD. Further investigational efforts, specifically in human populations, are warranted to improve our knowledge of the ECS in SAD.

Citation

Mashal Ahmed, Isabelle Boileau, Bernard Le Foll, Andre F Carvalho, Stefan Kloiber. The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2022 Jan-Feb;44(1):81-93